AzTrials
AzTrials

Urothelial Carcinoma BladderNCT04712201

En Bloc Bladder Tumor Resection: Prospective Randomized Study

A study testing En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT in people with Urothelial Carcinoma Bladder and Bladder Cancer, run by Fundacio Puigvert at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Urothelial Carcinoma Bladder, Bladder Cancer
What is being tested?
En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
300 participants
Where
1 siteSpain
Study dates
1 Apr 2018to 1 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
  • Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm

Who cannot join

  • Evidence of > 3 tumors or > 3 cm
  • Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
  • Computed tomography/magnetic resonance evidence of distant metastases

Trial locations and contacts

1 site in 1 country.

Spain1 site, 1 recruiting
  • Fundacio Puigvert

    Barcelona, 08025

    Andrea Gallioli, MD, 0034934169730, agallioli@fundacio-puigvert.es

    Recruiting

Other trials in Spain

About this study

Official title: En Bloc Bladder Tumor Resection: Prospective Randomized Evaluation of Monopolar, Bipolar and Laser Energy

INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. The current standard is based on conventional transurethral resection of bladder tumor, although high rates of recurrence have been reported following resection of the primary tumor. Given the importance of a correct initial diagnosis in these cases, en bloc transurethral resection has developed over the past 2 decades. This technique was born, according to the literature, with 3 main objectives: to improve the quality of the surgical piece for its anatomopathological reading, reduce the rate of postoperative complications and reduce the rate of relapses in the surgical bed. This technique is used as a common practice of tumor resection in other centers and has been shown in multiple publications that it does not increase surgical risk or negatively affect cancer results.

OBJECTIVE The objective of our study is to compare feasibility, perioperative complication rate, accuracy of staging and recurrence/progression rates when performing en bloc resection by means of different energies: monopolar, bipolar and laser energy.

Read more

MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be conducted including patients undergoing a transurethral resection of initial or recurrent bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote metastasis, whether lymphatic or organic, will be excluded.

Patients will be randomized into two groups:

  • Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according to the energy used (monopolar, bipolar, laser energy).
  • Group 2 (control): Conventional transurethral resection (n-120). It will be divided into 2 subgroups depending on the energy used (monopolar or bipolar).

A fact sheet will be given to the patient about the study and the signature of the informed consent will be requested in order to be included. The patient will be free to leave the study at any time without having to provide any justification and without affecting the treatment, intervention and follow-up that must be carried out.

The processing and storage of samples will be carried out in the pathological anatomy laboratory, according to standard clinical practice.

Patients will be monitored according to the usual clinical practice protocol (minimum 5-year follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert Foundation.

Being tested
En bloc transurethral resection of bladder tumor (TURBT), Conventional TURBT
Keywords
TURBT, En bloc, Urothelial cancer
Medical subject headings
Urinary Bladder Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • En bloc transurethral resection of bladder tumor (TURBT)Procedure or surgery

    En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy

  • Conventional TURBTProcedure or surgery

    Conventional transurethral resection of bladder tumor using monopolar and bipolar energy

Study groups in NCT04712201
Study groupRoleWhat they receive
En blocExperimentalEn bloc transurethral resection of the bladder
Receives: Procedure: En bloc transurethral resection of bladder tumor (TURBT)
ConventionalActive comparatorConventional transurethral resection of the bladder
Receives: Procedure: Conventional TURBT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Staging of bladder tumor

    Evaluation of muscle presence in the specimen

    Measured: Three years

Secondary outcomes (8)
  1. Intraoperative complications

    Bladder perforation grading, obturatory reflex, conversions to conventional TURB

    Measured: Three years

  2. Rate of planned adjuvant treatment

    Rate of planned postoperative single instillation of mitomycin/epirubicin

    Measured: Three years

  3. Post-operative complications

    Post-operative complications according to Clavien-Dindo System

    Measured: Three years

  4. Substaging T1 bladder cancer

    T1a, T1b and T1c

    Measured: Three years

  5. Recurrence-free survival

    Recurrence of bladder cancer

    Measured: Through study completion, an average of five years

  6. Progression-free survival

    Progression of bladder cancer

    Measured: Through study completion, an average of five years

  7. Disease-free survival

    Disease-free survival

    Measured: Through study completion, an average of five years

  8. Cancer specific survival

    Cancer specific survival

    Measured: Through study completion, an average of five years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jan 2021
  2. Study start1 Apr 2018
  3. Primary completion1 Jun 2021 (estimated)
  4. Study completion1 Apr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04712201
Sponsor's protocol ID
2017/09c
Status last verified
Jan 2021
First submitted
12 Jan 2021
Last updated
15 Jan 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Gallioli A, Diana P, Fontana M, Territo A, Rodriguez-Faba O, Gaya JM, Sanguedolce F, Huguet J, Mercade A, Piana A, Aumatell J, Bravo-Balado A, Algaba F, Palou J, Breda A. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022 Aug;5(4):440-448. doi: 10.1016/j.euo.2022.05.001. Epub 2022 May 23.

    PubMed 35618567

Questions about this trial

What is this clinical trial studying?

A study testing En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT in people with Urothelial Carcinoma Bladder and Bladder Cancer, run by Fundacio Puigvert at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Andrea Gallioli, MD (0034934169730, agallioli@fundacio-puigvert.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Staging of bladder tumor (time frame: Three years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04712201, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in